Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Diagonal Bio AB (publ)
  6. News
  7. Summary
    DIABIO   SE0015961826

DIAGONAL BIO AB (PUBL)

(DIABIO)
Delayed Nasdaq Stockholm  -  11:24 2022-12-02 am EST
0.8680 SEK   -5.24%
11/16Diagonal Bio AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
08/23Diagonal Bio AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
07/16Certain Shares of Diagonal Bio AB are subject to a Lock-Up Agreement Ending on 16-JUL-2022.
CI
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Diagonal Bio AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021

02/23/2022 | 01:30am EST

Diagonal Bio AB (publ) reported earnings results for the fourth quarter ended December 31, 2021. For the fourth quarter, the company reported sales was SEK 1.18 million compared to SEK 4.57 million a year ago. Revenue was SEK 1.18 million compared to SEK 4.66 million a year ago.

Net loss was SEK 3.02 million compared to SEK 0.226 million a year ago. Basic loss per share from continuing operations was SEK 0.33 compared to SEK 0.06 a year ago.


ę S&P Capital IQ 2022
All news about DIAGONAL BIO AB (PUBL)
11/16Diagonal Bio AB Reports Earnings Results for the Third Quarter and Nine Months Ended Se..
CI
08/23Diagonal Bio AB Reports Earnings Results for the Second Quarter and Six Months Ended Ju..
CI
07/16Certain Shares of Diagonal Bio AB are subject to a Lock-Up Agreement Ending on 16-JUL-2..
CI
05/11Diagonal Bio AB Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
02/23Diagonal Bio AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021
CI
02/23Diagonal Bio AB Reports Earnings Results for the Full Year Ended December 31, 2021
CI
2021Diagonal Bio AB has completed an IPO in the amount of SEK 40.053962 million.
CI
2021Diagonal Bio AB has filed an IPO in the amount of SEK 40.053962 million.
CI
More news
Financials
Sales 2021 8,67 M 0,84 M 0,84 M
Net income 2021 -11,7 M -1,12 M -1,12 M
Net cash 2021 20,8 M 2,00 M 2,00 M
P/E ratio 2021 -5,28x
Yield 2021 -
Capitalization 7,94 M 0,76 M 0,76 M
EV / Sales 2020 -
EV / Sales 2021 7,06x
Nbr of Employees 8
Free-Float -
Chart DIAGONAL BIO AB (PUBL)
Duration : Period :
Diagonal Bio AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DIAGONAL BIO AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
Jack Egelund Madsen Chief Executive Officer
Bo Per Gunnar Heander Chief Financial Officer
Eva Nilsagňrd Chairman
Andreas Nyberg Chief Scientific Officer
Carl Edvard Georg Hall Independent Director
Sector and Competitors
1st jan.Capi. (M$)
DIAGONAL BIO AB (PUBL)-83.54%1
MODERNA, INC.-28.20%70 055
IQVIA HOLDINGS INC.-22.83%40 441
LONZA GROUP AG-33.82%39 802
ALNYLAM PHARMACEUTICALS, INC.38.22%28 838
SEAGEN INC.-20.82%22 727